2023 Fall Clinical Dermatology Conference Highlights

Our Annual Fall Clinical Dermatology Conference is framed to improve our attendees' value and clinical skills through a uniquely designed educational experience. Check back here as we highlight key sessions and posters during the conference!

Thursday, October 19, 2023

Welcome Reception

Join Nick Brownstone, MD, and Jennifer Bares, MD, as they interview our attendees from the Welcome Reception!

80s Dance Party

Transport back to the 80s with our dance party!

Psoriasis & Psoriatic Arthritis – So Now What Do I Do?

In this 4-part lecture, Boni E. Elewski, MD, April W. Armstrong, MD, MPH, Erin E. Boh, MD, PhD, and Kristina Callis Duffin, MD, provided the audience with clinical...

Closing the Healthcare Gaps in the Management of Moderate-to-Severe Atopic Dermatitis with Biologics

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases encountered by dermatologists on a daily basis. In this session, Peter Lio, MD, and April W....

New Developments in Psoriasis: Clinical Insights for Dermatology Providers

While topical steroids are a mainstay of psoriasis treatment, side effects of long-term use limit their ability to be used on a daily basis. In this session, Alexandra...

What You Need To Know NOW About Cosmeceuticals

In this session, Cheri Frey, MD, provided an in-depth look at popular cosmeceutical ingredients on the market that all dermatologists should be aware of. Beginning with retinoids, Dr...

Poster of the Day: Effect of spesolimab on achieving sustained disease remission in patients with generalized pustular psoriasis: Results from the Effisayil 2 study

Generalized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening disease characterized by recurrent flares of widespread skin edema, erythema, and pustulation. Intravenous spesolimab, an anti-interleukin-36 receptor...

What You Need To Know NOW About Melanoma

Advancements in the detection and treatment of melanoma are occurring at a rapid pace. To help the audience keep track of everything, Darrell S. Rigel, MD, MS, provided...

Tips in the Use of IL-17 Inhibitors in Dermatology

Interleukin-17 inhibitors have become widely used in dermatology since secukinumab’s approval for psoriasis in 2015. In this session, Joseph F. Merola, MD, MMSc, and Bruce E. Strober, MD,...

What You Need To Know NOW About Atopic Dermatitis

Atopic dermatitis (AD) is one of the most commonly encountered skin diseases by dermatologists. John Koo, MD, gave the audience an excellent update on the diagnosis and treatment...

Therapeutic Pearls

In this highly attended lecture, Mark Lebwohl, MD, gave the audience therapeutic pearls for treating some of dermatology’s toughest diseases. Starting out with generalized pustular psoriasis (GPP), Dr...

Boehringe_Poster_7_Gottlieb_US_Claims_Database__Risk_of_All.png

Generalized pustular psoriasis (GPP) is a rare, chronic, neutrophilic skin disease characterized by recurring flares of widespread erythema, edema, coalescing pustules, and possible systemic symptoms that can be...

Therapeutic Hotline: Acne, Rosacea, AKs, Eczema, and Others

In this session, Gary Goldenberg, MD, took the audience on a whirlwind tour through the latest in treatment updates for common dermatologic conditions. Starting off with acne and...

What You Need To Know NOW About JAK Inhibitors

Janus kinase (JAK) inhibitors are one of the hottest topics in dermatology today. In this session, Raj Chovatiya, MD, PhD, MSCI, reviewed the science behind JAK inhibitor therapy...

What You Need To Know NOW About Hyperpigmentation

Hyperpigmentation has many different etiologies and can be a diagnostic and therapeutic challenge for dermatologists. In this session, Susan C. Taylor, MD, discussed tips for differentiating between the...

What You Need To Know NOW About Alopecia Areata

With the recent approval of baricitinib and ritlecitinib, alopecia areata (AA) is one of the most talked-about diseases in dermatology today. During this session, Natasha A. Mesinkovska, MD,...

Difficult Dermatology Conversations: Improving Care for Diverse Patient Populations

Poster of the Day: Rocatinlimab demonstrates improvements in patient-reported outcomes in adult patients with moderate-to-severe atopic dermatitis in a Phase 2b trial

Patients with moderate-to-severe atopic dermatitis (AD) often experience chronic pruritus, poor sleep, and decreased quality of life. Rocatinlimab, a monoclonal antibody that targets OX40, is being investigated for...

30 Tips in 30 Minutes

This multispeaker session is always an audience favorite; this year, the panel included medical, surgical, as well as practice management tips. Erin Boh, MD, PhD, kicked off the...

What’s New in JAAD

To help the audience stay up to date on recent literature publications, Dirk Elston, MD, reviewed interesting articles published in the Journal of the American Academy of Dermatology...

What’s New in SKIN

To round out the morning review of dermatology literature, Roger I. Ceilley, MD, delighted the audience with a look back at the past year for SKIN: The Journal...

Boxed Warnings: What Do They Really Mean To You?

The approval of multiple novel JAK inhibitors for inflammatory dermatoses such as atopic dermatitis and alopecia areata has left many dermatologists wondering how to deal with the FDA-mandated...

Poster of the Day: Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

BMS_Poster_6_Armstrong_Deucravacitinib_3_year_safety_and_efficacy.png

Deucravacitinib, an oral selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who...